Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
J Neurochem. 2019 Mar;148(5):652-668. doi: 10.1111/jnc.14480. Epub 2018 Aug 9.
Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) is an autosomal recessive lysosomal storage disease caused by loss-of-function mutations in CLN3. Symptoms appear between 5 and 10 years of age, beginning with blindness and seizures, followed by progressive cognitive and motor decline, and premature death. Glial activation and impaired neuronal activity are early signs of pathology in the Cln3 mouse model of JNCL, whereas neuron death occurs much later in the disease process. We previously reported that Cln3 microglia are primed toward a pro-inflammatory phenotype typified by exaggerated caspase 1 inflammasome activation and here we extend those findings to demonstrate heightened caspase activity in the Cln3 mouse brain. Based on the ability of caspase 1 to cleave a large number of substrates that have been implicated in JNCL pathology, we examined the functional implications of caspase 1 inflammasome activity by crossing Cln3 and caspase 1-deficient mice to create Cln3 /Casp-1 animals. Caspase 1 deletion influenced motor behavior deficits and astrocyte activation in the context of CLN3 mutation, since both were significantly reversed in Cln3 /Casp-1 mice, with phenotypes approaching that of wild-type animals. We also report a progressive age-dependent reduction in whisker length in Cln3 mice that was partially caspase 1-dependent. However, not all CLN3 phenotypes were reversed following caspase 1 deletion, since no significant differences in lysosomal accumulation or microglial activation were observed between Cln3 and Cln3 /Casp-1 mice. Although the molecular targets of aberrant caspase 1 activity in the context of CLN3 mutation remain to be identified, our studies suggest that caspase 1 may represent a potential therapeutic target to mitigate some attributes of CLN3 disease. This article is part of the Special Issue "Lysosomal Storage Disorders".
青少年神经元蜡样脂褐质沉积症(JNCL)是一种常染色体隐性溶酶体贮积病,由 CLN3 功能丧失突变引起。症状出现在 5 到 10 岁之间,开始时失明和癫痫发作,随后认知和运动功能逐渐下降,并导致早逝。胶质细胞激活和神经元活动受损是 JNCL Cln3 小鼠模型中病理学的早期迹象,而神经元死亡发生在疾病过程的后期。我们之前报道 Cln3 小胶质细胞被预先设定为促炎表型,其特征是半胱天冬酶 1 炎性小体激活过度,在这里我们扩展了这些发现,以证明 Cln3 小鼠大脑中的半胱天冬酶活性升高。基于半胱天冬酶 1 能够切割大量与 JNCL 病理学有关的底物的能力,我们通过将 Cln3 和半胱天冬酶 1 缺陷小鼠杂交来创建 Cln3/Casp-1 动物,以检查半胱天冬酶 1 炎性小体活性的功能意义。由于在 Cln3 /Casp-1 小鼠中,这两种情况都得到了显著逆转,表型接近野生型动物,因此半胱天冬酶 1 的缺失影响了 CLN3 突变背景下的运动行为缺陷和星形胶质细胞激活。我们还报告了 Cln3 小鼠胡须长度的进行性年龄依赖性减少,这在一定程度上依赖于半胱天冬酶 1。然而,在半胱天冬酶 1 缺失后,并非所有 CLN3 表型都得到逆转,因为在 Cln3 和 Cln3 /Casp-1 小鼠之间没有观察到溶酶体积累或小胶质细胞激活的显著差异。尽管在 CLN3 突变的情况下,异常半胱天冬酶 1 活性的分子靶标仍有待确定,但我们的研究表明,半胱天冬酶 1 可能代表一种潜在的治疗靶点,可以减轻 CLN3 疾病的某些特征。本文是“溶酶体贮积症”特刊的一部分。